Core Viewpoint - The company, Fuhong Hanlin (02696), has seen a significant stock price increase following the announcement of successful clinical trials for its drug HLX43, indicating strong potential in the lung cancer treatment market [1] Group 1: Clinical Developments - Fuhong Hanlin has completed the first patient dosing in the U.S. for the international multicenter phase II clinical study of HLX43, a PD-L1 targeted antibody-drug conjugate for advanced non-small cell lung cancer (NSCLC) patients [1] - The company has had 10 lung cancer studies accepted for presentation at the 2025 World Conference on Lung Cancer (WCLC), focusing on three core innovative drugs: anti-PD-1 monoclonal antibody H drug, anti-EGFR monoclonal antibody HLX07, and the first PD-L1 ADC HLX43 entering phase II clinical trials globally [1] Group 2: Market Potential - Citigroup has indicated that Fuhong Hanlin will soon present the latest data on HLX43 at WCLC, which could further demonstrate its potential in treating NSCLC [1] - If HLX43 maintains an objective response rate (ORR) of 35% to 40% and a median progression-free survival (mPFS) of approximately 5.5 months in larger samples, the data will be highly persuasive [1]
复宏汉霖盘中涨超8% HLX43完成美国首例患者给药 旗下三款核心产品将亮相WCLC